← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Teneobio, Inc.
Newark, CA
$1,701,500
Total funding
6
Grants
Funding over time
peak $889.3K · FY2018–20$1M$750K$500K$250K$0
'18
'19
'20
Funding mix
By agency
NIH$1,701,500 · 6
By mechanism
R43$1,701,500 · 6
Investigators at Teneobio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a PSMA x PSMA x CD3 trivalent, bispecific T-cell engaging antibody to treat Castration Resistant Prostate Carcinoma$299,473
R43 · FY2018 · CA
Development of an Frα x Frα x CD3 trivalent, biparatopic T-cell engaging antibody to treat high grade serous carcinoma$298,345
R43 · FY2019 · CA
Bispecific Antibodies Directed to CD3and HBsAg to Treat Chronic Hepatitis B Virus$296,876
R43 · FY2019 · AI
CD38 enzyme blocking heavy chain antibodies for Inflammatory Bowel Diseases$294,124
R43 · FY2019 · AI
Development of novel heavy chain antibody-based therapeutics for polyomavirus infections$291,478
R43 · FY2018 · AI
Inhibition of CD38 NADase by anti-CD38 antibody: a novel therapy for systemic scleroderma$221,204
R43 · FY2020 · AR